avapro has been researched along with Focal Segmental Glomerulosclerosis in 3 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 5.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| " Sparsentan was safe and well tolerated." | 2.87 | DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. ( Adler, S; Campbell, KN; Chaudhuri, A; Derebail, VK; Gambaro, G; Gesualdo, L; Gipson, DS; Hogan, J; Komers, R; Lieberman, K; Marder, B; Meyers, KE; Mustafa, E; Nelson, P; Radhakrishnan, J; Srivastava, T; Stepanians, M; Tesar, V; Trachtman, H; Zhdanova, O, 2018) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 1.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trachtman, H | 1 |
| Nelson, P | 1 |
| Adler, S | 1 |
| Campbell, KN | 1 |
| Chaudhuri, A | 1 |
| Derebail, VK | 1 |
| Gambaro, G | 1 |
| Gesualdo, L | 1 |
| Gipson, DS | 1 |
| Hogan, J | 1 |
| Lieberman, K | 1 |
| Marder, B | 1 |
| Meyers, KE | 1 |
| Mustafa, E | 1 |
| Radhakrishnan, J | 1 |
| Srivastava, T | 1 |
| Stepanians, M | 1 |
| Tesar, V | 1 |
| Zhdanova, O | 1 |
| Komers, R | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| O'Donnell, MP | 1 |
| Crary, GS | 1 |
| Oda, H | 1 |
| Kasiske, BL | 1 |
| Powell, JR | 1 |
| Keane, WF | 1 |
1 trial available for avapro and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Child; Creatinine; Dose-Response R | 2018 |
2 other studies available for avapro and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca | 2010 |
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Co | 1997 |